Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER)

Glassberg, Marilyn K.; Minkiewicz, Julia; Toonkel, Rebecca L.; Simonet, Emmanuelle S.; Rubio, Gustavo A.; DiFede, Darcy L.; Shafazand, Shirin; Khan, Aisha; Pujol, Marietsy V.; LaRussa, Vincent F.; Lancaster, Lisa; Rosen, Glenn D.; Fishman, Joel E.; Mageto, Yolanda; Mendizabal, Adam; Hare, Joshua M.

doi:10.1016/j.chest.2016.10.061

Cited by 200 publications

(178 citation statements)

References 34 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Temporal relationship suggested stem cell treatment as the likely trigger. In the recent AETHER study, treatment emergent adverse events were those occurring within 4 weeks of stem cell treatment [10]; our case met that definition. The clinical course made infection unlikely.…”

Section: Discussionmentioning

confidence: 99%

“…Recent results of the AE-THER study revealed two deaths during the study period, one from IPF exacerbation and one from disease progression, over a 15-month period after IV stem cell therapy. Neither death was reported as being related to the study intervention [10]. However, due to the small samples, the diversity of disease states, and different methods employed, there is much information lacking regarding the short-term and long-term safety of the procedures.…”

Section: Discussionmentioning

confidence: 99%

“…Sources have included bone marrow [8][9][10], adipose tissue [11], lung (from both live and deceased donors) [12], and placentas [13]. Once cultivated, several ways of reintroducing stem cells have been described, including by IV infusion [8,10,14], nebulization and bronchoscopy [11,12].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Acute Respiratory Failure in a Patient With Idiopathic Pulmonary Fibrosis Following Nebulized and Intravenous Stem Cell Therapy

et al. 2017

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is an uncommon disease with a poor prognosis. Recently, two medications were approved to slow progression of disease. However, due to the limited treatment options available, patients and their families often look to experimental and off-label treatments for support. One such option is stem cell therapy, which can be delivered in a variety of ways. Stem cells are being utilized both in and out of the context of closely monitored clinical trials. However, there is little evidence regarding the safety and efficacy of stem cell therapy for patients with IPF. Here we describe a case of a patient who received intravenous and nebulized stem cell therapy, which was followed by an acute exacerbation of his IPF. The exacerbation was successfully treated with corticosteroids and supportive care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acute Respiratory Failure in a Patient With Idiopathic Pulmonary Fibrosis Following Nebulized and Intravenous Stem Cell Therapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A small phase I study of bone-marrow derived mesenchymal stem cell infusion in mild to moderate IPF patients showed no treatment related serious adverse events 76 , but there remain some concerns that stem cells 79 . Most precision medicine discussion to date has focused on molecular and genetic markers in identifying distinct endotypes 77 .…”

Section: Stem Cell Therapymentioning

confidence: 99%

Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?

Wu¹,

Kaner²,

Martínez³

2017

BRN

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a disease of chronic progressive interstitial pneumonia limited to the lungs. There is growing interest in this disorder as its incidence has increased over time in most countries around the world. This is likely related to an aging population, increased awareness of the disease, and increasingly sensitive imaging technology. Considerable energy has been devoted to creating an improved understanding of its pathogenesis and developing novel therapies. Although dozens of drugs have been studied for the treatment of IPF, only two, pirfenidone and nintedanib, are currently recommended by international guidelines to slow the disease progression. We review the drugs that have been evaluated as IPF therapy over the past three decades, including the currently recommended pirfenidone and nintedanib, note ongoing clinical trials and provide insights into future directions. (BRN Rev. 2017;3:86-101)

show abstract

Section: Stem Cell Therapymentioning

confidence: 99%